Search result for 'generic cancer drug'

Cipla receives USFDA approval for its generic cancer treatment drug, paclitaxel protein-bound particles, a therapeutic equivalent to Bristol Myers Squibb's Abraxane. The drug is expected to launch...

Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has received USFDA approval to market Pazopanib Tablets (200 mg) in the US. The drug is therapeutically equivalent to Novartis' Votrient...

Natco Pharma has submitted an ANDA to the USFDA for a generic version of Novartis' Tabrecta, a cancer drug. The company expects to be eligible for 180 days of marketing exclusivity.

Lupin has launched a generic version of Doxorubicin Hydrochloride Liposome Injection (Doxil) in the US market, treating ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma.

Alembic Pharmaceuticals receives USFDA approval to market generic Nelarabine Injection for cancer treatment, expanding its portfolio to 211 ANDA approvals.

Zydus Lifesciences has partnered with MSN Laboratories to bring a generic version of the cancer drug Cabozantinib to the US market, aiming to provide affordable treatment options.